DAXOR CORP Stock Price, News & Analysis

Daxor Corporation (NYSE: DXR) reported a significant 61% increase in Q1 2021 revenue year-over-year, attributed to the easing of COVID restrictions. The company opened five new customer accounts utilizing its BVA-100 Blood Volume Analyzer and anticipates more acquisitions in Q3 2021, expanding its presence in major medical centers. Daxor is enhancing its sales team to support growth, with expectations to access over 70% of client hospitals by the end of Q2 2021. The company is also advancing next-generation diagnostic technologies that aim to improve patient outcomes and operational efficiency.

Daxor Corporation (NYSE: DXR) announces the start of a multi-center clinical trial with Veterans Affairs Medical Centers to assess Blood Volume Analysis (BVA) for managing acute decompensated heart failure (ADHF) using the BVA-100 blood test. The NIH intends to fund this landmark study, which aims to enhance treatment outcomes for over 6 million heart failure patients in the U.S. Previous data indicates that BVA-100 guided care could reduce patient mortality by over 82% and readmissions by 56%. The study is vital for validating Daxor's clinical guidance system and advancing heart failure management.

Daxor Corporation (NYSE: DXR) announced new findings regarding the BVA-100 blood test's effectiveness in managing Postural Tachycardia Syndrome (POTS). Published in the Journal of the American College of Cardiology, the study demonstrated that a high sodium diet increased plasma volume and reduced heart rate in POTS patients. The BVA-100 test provides accurate blood volume measurements, affirming its role as a crucial tool for treatment optimization in POTS. Daxor continues to position itself as a leader in blood volume measurement technology.

Daxor Corporation (NYSE: DXR) announces that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. His presentation on March 24 at 12:30 PM EDT will cover the company's business model, growth strategy, and advancements in blood volume measurement technology, including updates on research and contracts with the US Department of Defense. Investors can register to view the presentation and request one-on-one meetings with Feldschuh.

Daxor Corporation (NYSE: DXR) announced that President and CEO Michael Feldschuh will present at the 2021 Emerging Growth Virtual Conference on March 17-19, 2021. He will discuss Daxor's recent achievements, including revenue growth, research advancements, and new contracts with the US Department of Defense. The company's BVA-100® blood test aims to improve management in critical care, COVID-19, and heart failure. Investors can view the presentation online and request one-on-one meetings with Feldschuh afterward.

Daxor Corporation (NYSE: DXR) has secured a $750,000 phase-two contract from the USAF to enhance its blood volume measurement technology. This contract marks the fourth award from the DoD in two years, totaling over $2 million. The funding will facilitate the development of a new fluorescent tracer and optical sensing technology, expanding the capabilities of the BVA-100 Blood Volume Analyzer for both military and civilian applications. The innovative system aims to improve patient resuscitation and treatment outcomes.

Daxor Corporation (NYSE: DXR) reported a 50.4% revenue increase for its operating division in fiscal 2020, driven by strong sales and leasing of its blood volume analysis systems and military contracts from the US Department of Defense. The company’s NAV rose to $3.89, a 14% increase from $3.41 in 2019. Additionally, Daxor is advancing next-generation BVA technology with support from the NIH and ongoing clinical studies. The commercialization efforts led by new VP Jean Oertel aim to further expand market reach and enhance revenue growth in the coming year.